香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2025年12月24日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 证券代码：600276 证券简称：恒瑞医药 公告编号：临2025-20 ...

Core Viewpoint - The article highlights the current premium rates of AH shares, with Northeast Electric (00042), Zhejiang Shibao (01057), and Hongye Futures (03678) leading in premium rates, while Ningde Times (03750), China Merchants Bank (03968), and Hengrui Medicine (01276) have the lowest premium rates. Group 1: Top AH Share Premium Rates - Northeast Electric (00042) has a premium rate of 900.00% with a deviation value of 22.98% [1] - Zhejiang Shibao (01057) has a premium rate of 401.23% with a deviation value of 124.99% [1] - Hongye Futures (03678) has a premium rate of 283.18% with a deviation value of 10.66% [1] - The top ten AH shares by premium rate include companies like Sinopec Oilfield Service (01033) at 273.91% and Chenming Paper (01812) at 252.00% [1] Group 2: Bottom AH Share Premium Rates - Ningde Times (03750) has a premium rate of -11.39% with a deviation value of -3.74% [1] - China Merchants Bank (03968) has a premium rate of -2.91% with a deviation value of -2.00% [1] - Hengrui Medicine (01276) has a premium rate of 3.01% with a deviation value of 0.10% [1] - Other companies in the bottom ten include Midea Group (00300) at 8.90% and Weichai Power (02338) at 9.74% [1] Group 3: Deviation Values of AH Shares - The highest deviation values are led by Zhejiang Shibao (01057) at 124.99%, followed by Junda Co., Ltd. (02865) at 58.52% and Nanjing Panda Electronics (00553) at 32.51% [2] - The lowest deviation values are seen in GAC Group (02238) at -24.43%, followed by Dongfang Electric (01072) at -8.78% and Jiangsu Ninghu Expressway (00177) at -8.68% [3]

Group 1: Industry Overview - In October, the total sales of pharmaceutical products in mainland China decreased by 3% year-on-year, a significant drop from the 6.8% growth in September [1] - Hospital channel sales fell by 3.3% year-on-year, compared to a 7.1% increase in the previous month [1] - Retail channel sales remained flat year-on-year, a slowdown from the 2.4% growth in September [1] Group 2: Company Performance - Hansoh Pharmaceutical (03692) recorded the highest year-on-year growth among peers in October at 8.6%, with most key products showing double-digit month-on-month growth, except for PEG-loxenatide [1] - The report maintains a "Buy" rating for Hansoh Pharmaceutical with a target price of HKD 45 [1] - Hengrui Medicine (01276) faced pressure on multiple key products, with total sample sales growing by only 2% year-on-year in October, and specific products like butorphanol, ioversol, and sevoflurane seeing declines of 49.1%, 0.5%, and 10.8% respectively [1] - Hengrui's A-share target price is set at RMB 57.7, with a "Underperform" rating [1] Group 3: Additional Company Insights - China Biologic Products (01177) showed a mixed performance in October, with core products anlotinib and glycyrrhizic acid growing by 6.5% and 4.4% year-on-year, while budesonide and esomeprazole saw declines of 28.5% and 39.4% respectively [2] - The revenue forecasts for 2026 and 2027 were lowered by 0.2% and 0.4% respectively due to the sales performance, with the target price adjusted from HKD 9.4 to HKD 8.3, while maintaining a "Buy" rating based on pipeline potential [2] - CSPC Pharmaceutical Group (01093) continued to experience low sales for several key drugs, maintaining an "Underperform" rating with a target price of HKD 7.2 [2]

Core Insights - The "Golden Award" annual outstanding company selection by Gelonghui will reveal a list of notable companies, including Aneng Logistics, BYD, Oriental Yuhong, and others, recognized for their brand value in the capital market [1] - The "Annual Brand Value Award (Large Market Capitalization)" aims to honor companies with the highest brand value, emphasizing the importance of brand differentiation, recognition, and customer loyalty [1][2] Group 1: Award Recipients - Ten companies received the "Annual Brand Value Award (Large Market Capitalization)" including Aneng Logistics (09956.HK), BYD (002594.SZ/01211.HK), and Lenovo Group (00992.HK) [1] - The award selection process involved quantitative data analysis and expert review to determine the final results [1] Group 2: Evaluation Criteria - The evaluation of brand value considered multiple factors such as brand differentiation, recognition, and customer loyalty [1] - The aim of the award is to create a reference for the most valuable listed companies and unicorns in the investment community [2]

Core Insights - The article highlights the top and bottom AH share premium rates as of December 22, with Northeast Electric (00042), Zhejiang Shibao (01057), and Hongye Futures (03678) leading in premium rates, while CATL (03750), China Merchants Bank (03968), and Hansoh Pharmaceutical (01276) are at the bottom [1][2][3] Group 1: Top AH Share Premium Rates - Northeast Electric (00042) has a premium rate of 864.29% with a deviation value of -11.58% [2][5] - Zhejiang Shibao (01057) shows a premium rate of 354.83% and a deviation value of 86.04% [2][4] - Hongye Futures (03678) has a premium rate of 274.70% with a deviation value of 3.11% [2][4] Group 2: Bottom AH Share Premium Rates - CATL (03750) has a premium rate of -12.58% and a deviation value of -4.76% [3][5] - China Merchants Bank (03968) shows a premium rate of -1.90% with a deviation value of -1.08% [3][5] - Hansoh Pharmaceutical (01276) has a premium rate of 3.44% and a deviation value of 0.44% [3][5] Group 3: Deviation Values - Zhejiang Shibao (01057) leads in deviation value at 86.04% [4] - Junda Co. (02865) follows with a deviation value of 46.60% [4] - COSCO Shipping Development (02866) has a deviation value of 19.01% [4] Group 4: Negative Deviation Values - GAC Group (02238) has the lowest deviation value at -26.02% [5] - Yangtze Optical Fibre and Cable (06869) shows a deviation value of -16.85% [5] - Andeli Juice (02218) has a deviation value of -14.47% [5]

Group 1 - The core point of the article is that Heng Rui Medicine (01276.HK) announced that its subsidiary, Beijing Shengdi Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of SHR-2906 injection, which will commence soon [1] Group 2 - The approval signifies a positive development for the company, indicating progress in its drug development pipeline [1] - The initiation of clinical trials is a critical step towards potential commercialization of SHR-2906, which may enhance the company's market position [1] - This news may attract investor interest, reflecting the company's ongoing commitment to innovation in the pharmaceutical sector [1]

Core Viewpoint - Heng Rui Medicine (01276.HK) has received approval from the National Medical Products Administration for clinical trial notifications for multiple drug candidates, indicating progress in its research and development pipeline [1] Group 1: Company Developments - The company and its subsidiaries, Shanghai Heng Rui Medicine Co., Ltd., Shandong Shengdi Medicine Co., Ltd., and Chengdu Shengdi Medicine Co., Ltd., have been granted approval for clinical trials of HRS-6208 capsules, HRS-6209 capsules, HRS-8080 tablets, HRS-1358 tablets, and HRS-5041 tablets [1]

Core Viewpoint - Heng Rui Medicine (01276) announced that its subsidiary, Beijing Shengdi Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of SHR-2906 injection, which will commence shortly [1] Group 1: Product Development - SHR-2906 injection is a self-developed therapeutic biological product aimed at regulating glucose and lipid metabolism, controlling weight, and improving the metabolic environment in the body [1] - The drug is expected to have a synergistic effect in reducing energy intake and promoting energy expenditure, potentially offering clinical efficacy in treating overweight and obesity [1] - Currently, there are no similar drugs approved for market use domestically or internationally [1] Group 2: Financial Investment - The cumulative research and development investment for the SHR-2906 injection project has reached approximately 17.06 million yuan [1]

Core Viewpoint - Heng Rui Medicine (01276.HK) has received approval from the National Medical Products Administration for clinical trials of its injectable leuprolide acetate microspheres, indicating a significant step in its product development pipeline [1] Group 1 - The company’s subsidiary, Shanghai Heng Rui Medicine Co., Ltd., is set to initiate clinical trials for the new drug [1] - The approval marks a crucial milestone in the company's efforts to expand its product offerings in the pharmaceutical market [1]

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of SHR-9539 injection and HRS-3738 tablets, marking significant advancements in their drug development pipeline [1] Group 1: SHR-9539 Injection - SHR-9539 injection is a Class 1 therapeutic biological product that targets multiple myeloma cells by recruiting and activating T cells [1] - There are currently no similar drugs approved for market in China [1] - The total research and development investment for the SHR-9539 injection project has reached approximately 39.93 million yuan [1] Group 2: HRS-3738 Tablets - HRS-3738 tablets are a next-generation CRBNE3 ubiquitin ligase modulator that affects the proliferation of hematological tumor cells by degrading specific substrates [1] - This drug has strong substrate degradation capabilities and potential advantages in overcoming drug resistance [1] - There are no similar drugs approved for market domestically or internationally [1] - The total research and development investment for the HRS-3738 tablet project has reached approximately 63.63 million yuan [1]